Related Experiment Video
Updated: Aug 16, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Immature and mature myocardium in the pathophysiology of hypertrophic cardiomyopathy
Jan M Federspiel1, Steven Lee Medarev2, Jochen Pfeifer3
1Institute of Legal Medicine, Saarland University, Faculty of Medicine, Homburg, Saar, Germany.
Insights
Hypertrophic cardiomyopathy (HCM) involves myocardial thickening due to genetic and non-genetic factors. Embryonic factors may explain uniform pathological changes, suggesting potential for targeted therapies.
Area of Science:
- Cardiology
- Genetics
- Developmental Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is the most common inherited heart muscle disease.
- Pathognomonic feature is left ventricular wall thickening, often due to sarcomeric protein gene variants.
- Complex pathophysiology involves genetic and non-genetic factors, leading to diastolic dysfunction and hypercontractility.
Purpose of the Study:
- To compare immature and mature myocardium in HCM.
- To assess the impact of embryological factors on HCM pathophysiology.
- To explore fetal-like reprogramming as a unifying mechanism in HCM.
Main Methods:
- Literature review comparing immature and mature myocardium.
- Analysis of molecular differences in sarcomeric variant-affected myocardium.
- Assessment of early postnatal period's role in hypertrophy.
Main Results:
- Differences exist at the molecular level between immature and mature myocardium with sarcomeric variants.
- The early postnatal period is crucial for sarcomeric alterations driving hypertrophy.
- Shared downstream pathological changes suggest fetal-like reprogramming as a potential unifying mechanism.
Conclusions:
- Embryological factors and myocardial remodeling are key to HCM pathophysiology.
- Fetal-like reprogramming may bridge immature and mature myocardium in HCM.
- Further research into embryonic factors could lead to targeted HCM therapies.
Abstract:
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The pathognomonic finding is the thickening of the myocardial layer, usually of the left ventricular wall. This hypertrophy is often caused by variants in genes encoding sarcomeric proteins. Additionally, non-genetic factors contribute to the complex pathophysiology. Interestingly, these genetic and non-genetic factors result in quite uniform pathological changes, e.g., diastolic dysfunction and hypercontractility can be regarded as pathophysiological hallmarks of the disease. A potential explanation for this might be that embryological factors along with a first adaptive and later maladaptive myocardial remodeling prime myocardial hypertrophy. The present review compares the immature and mature myocardium to further assess the impact of embryological factors on the pathophysiology of HCM. According to the literature, there are differences between the immature and mature myocardium affected by sarcomeric variants at the molecular level. At the same time, the early postnatal period seems to be fundamental to sarcomeric alterations that later drive hypertrophy. Given the shared down-stream pathological changes, fetal-like reprogramming might be the pathophysiological molecular merging point of immature and mature myocardium finally driving the maladaptive hypertrophic remodeling in HCM. More research on such embryonic factors might allow for further HCM-specific targeted therapy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Heart Failure II: Pathophysiology
Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Cardiomyopathy V: Interprofessional Care
Cellular Adaptation II: Hypertrophy

